PMID: 6107545Oct 25, 1980Paper

Cold lymphocytotoxins: an important cause of acute tubular necrosis occurring immediately after transplantation

Lancet
P I LoboL Rudolf

Abstract

Cold-reactive lymphocytotoxins, present in some renal-transplant recipients, may be an important cause of the acute tubular necrosis (ATN) that commonly occurs immediately after transplantation. In a study of transplantation of optimally preserved cadaveric kidneys obtained from heart-beating donors, ATN was found in 10 of 17 recipients with cold antibodies and in only 1 of 21 recipients without such antibodies. Warming of the allograft after completion of anastomosis significantly reduced the incidence of ATN at 18% in recipients with cold antibodies. When pairs of reicpients with cold antibodies were transplanted with identically preserved cadaveric kidneys from single donors ATN was observed only in recipients whose donor kidney was not warmed. ATN may result from antibody-medicated damage to vascular endothelial cells during the brief period when the recipient's blood starts flowing into a "cold" allograft.

References

Jun 18, 1977·Lancet·P J MorrisM S Dunnill
Mar 1, 1980·Transplantation·D BrophyC M Kjellstrand

❮ Previous
Next ❯

Citations

Apr 9, 1998·The Surgical Clinics of North America·V K Rao
Oct 1, 1981·The New England Journal of Medicine·D Rodbard
Jan 1, 1982·Immunological Reviews·P J Morris, A Ting
Jan 1, 1983·Clinical and Experimental Dialysis and Apheresis·K V Rao, C M Kjellstrand

❮ Previous
Next ❯

Related Concepts

Related Feeds

Acute viral rhinopharyngitis

Acute viral rhinopharyngitis, also known as "common cold", is an acute, self-limiting viral infection of the upper respiratory tract involving the nose, sinuses, pharynx and larynx. Discover the latest research on acute viral rhinopharyngitis here.

Allogenic & Autologous Therapies

Allogenic therapies are generated in large batches from unrelated donor tissues such as bone marrow. In contrast, autologous therapies are manufactures as a single lot from the patient being treated. Here is the latest research on allogenic and autologous therapies.